Literature DB >> 9322866

Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses.

M Laitinen1, T Pakkanen, E Donetti, R Baetta, J Luoma, P Lehtolainen, H Viita, R Agrawal, A Miyanohara, T Friedmann, W Risau, J F Martin, M Soma, S Ylä-Herttuala.   

Abstract

We studied the efficiency of plasmid/liposome complexes, Moloney murine leukemia virus-derived (MMLV) retroviruses, pseudotyped vesicular stomatitis virus protein-G (VSV-G)-containing retroviruses, and adenoviruses in delivering genes into the rabbit carotid artery using a silastic collar applied to the adventitia. This method was used for gene transfer because (a) it provides a gene delivery reservoir; (b) no intraluminal manipulations are performed; (c) installation of the collar induces arterial smooth muscle cell (SMC) proliferation and enhances retroviral gene transfer efficiency where target cell proliferation is required. The transfer of the beta-galactosidase (lacZ) marker gene to the adventitia and media occurred with all gene transfer systems. Adenoviruses also transferred the beta-galactosidase gene to some endothelial cells. After 5 days, adenoviral vectors produced the highest gene transfer efficiency with up to 10%+/-6% of cells showing beta-galactosidase activity. Pseudotyped VSV-G retroviruses were also effective in achieving gene transfer in 0.05%+/-0.03% of cells in the adventitia and media. Plasmid/liposome complexes and MMLV retroviruses infected 0.05%+/-0.03% and <0.01%+/-0.01% of cells, respectively. It is concluded that replication-deficient adenoviruses, VSV-G pseudotyped retroviruses, and plasmid/liposome complexes can be used for gene transfer to the arterial wall using the collar method. Because the endothelium remains anatomically present throughout the experiments, the model may be useful for the gene transfer studies involving diffusible or secreted gene products that primarily act on the endothelium. Effects on medial SMC and even endothelium can be achieved from the adventitial side, suggesting an alternative route for the delivery of therapeutically useful genes into the arterial wall.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322866     DOI: 10.1089/hum.1997.8.14-1645

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  12 in total

Review 1.  Clinical applications of vascular gene therapy.

Authors:  J Rutanen; T T Rissanen; A Kivelä; I Vajanto; S Ylä-Herttuala
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 2.  Vectors for gene therapy of cardiovascular disease.

Authors:  J F Dedieu; A Mahfoudi; A Le Roux; D Branellec
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

3.  A novel combination of promoter and enhancers increases transgene expression in vascular smooth muscle cells in vitro and coronary arteries in vivo after adenovirus-mediated gene transfer.

Authors:  C E Appleby; P A Kingston; A David; C A Gerdes; P Umaña; M G Castro; P R Lowenstein; A M Heagerty
Journal:  Gene Ther       Date:  2003-09       Impact factor: 5.250

Review 4.  Radionuclide reporter gene imaging for cardiac gene therapy.

Authors:  Masayuki Inubushi; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 9.236

Review 5.  Gene transfer to the vasculature: historical perspective and implication for future research objectives.

Authors:  Sarah J George; Andrew H Baker
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

6.  Quiescence, cell viability, apoptosis and necrosis of smooth muscle cells using different growth inhibitors.

Authors:  J Pelisek; S Armeanu; S Nikol
Journal:  Cell Prolif       Date:  2001-10       Impact factor: 6.831

Review 7.  Contrast ultrasound and targeted microbubbles: diagnostic and therapeutic applications for angiogenesis.

Authors:  Alexandra H Smith; Hiroko Fujii; Michael A Kuliszewski; Howard Leong-Poi
Journal:  J Cardiovasc Transl Res       Date:  2011-05-03       Impact factor: 4.132

Review 8.  New vectors and strategies for cardiovascular gene therapy.

Authors:  Agnieszka Jazwa; Alicja Jozkowicz; Jozef Dulak
Journal:  Curr Gene Ther       Date:  2007-02       Impact factor: 4.391

Review 9.  Gene therapy for restenosis: current status.

Authors:  Juha Rutanen; Johanna Markkanen; Seppo Ylä-Herttuala
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Dotted collar placed around carotid artery induces asymmetric neointimal lesion formation in rabbits without intravascular manipulations.

Authors:  Antti Kivelä; Juha Hartikainen; Seppo Ylä-Herttuala
Journal:  BMC Cardiovasc Disord       Date:  2012-10-17       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.